Capital Asset Advisory Services LLC Purchases Shares of 28,151 Hims & Hers Health, Inc. $HIMS

Capital Asset Advisory Services LLC purchased a new position in Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 28,151 shares of the company’s stock, valued at approximately $998,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HIMS. Vanguard Group Inc. lifted its stake in shares of Hims & Hers Health by 4.5% during the 3rd quarter. Vanguard Group Inc. now owns 19,518,015 shares of the company’s stock valued at $1,107,062,000 after buying an additional 844,991 shares in the last quarter. Capital World Investors increased its stake in Hims & Hers Health by 1.2% in the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock worth $1,065,399,000 after buying an additional 223,892 shares in the last quarter. Farallon Capital Management LLC raised its holdings in Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after acquiring an additional 2,533,271 shares during the period. State Street Corp raised its holdings in Hims & Hers Health by 1.9% during the third quarter. State Street Corp now owns 7,173,214 shares of the company’s stock valued at $406,865,000 after acquiring an additional 132,384 shares during the period. Finally, Invesco Ltd. lifted its position in shares of Hims & Hers Health by 62.7% in the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after acquiring an additional 1,600,004 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $21.39 on Wednesday. The firm has a market capitalization of $4.88 billion, a PE ratio of 41.95, a PEG ratio of 2.60 and a beta of 2.55. The stock’s fifty day moving average is $22.39 and its 200 day moving average is $36.29. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The company had revenue of $617.82 million during the quarter, compared to analyst estimates of $619.48 million. During the same period in the previous year, the firm earned $0.11 earnings per share. Hims & Hers Health’s quarterly revenue was up 28.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Activity

In related news, insider Irene Becklund sold 5,529 shares of Hims & Hers Health stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $136,511.01. Following the completion of the transaction, the insider directly owned 8,752 shares of the company’s stock, valued at approximately $216,086.88. The trade was a 38.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Soleil Boughton sold 4,812 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $118,808.28. Following the transaction, the insider owned 308,831 shares in the company, valued at $7,625,037.39. The trade was a 1.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 125,767 shares of company stock worth $3,238,953 over the last 90 days. Insiders own 17.71% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Bank of America raised Hims & Hers Health from an “underperform” rating to a “neutral” rating and lifted their target price for the company from $12.50 to $23.00 in a research note on Tuesday, March 10th. Deutsche Bank Aktiengesellschaft boosted their price target on Hims & Hers Health from $25.00 to $28.00 and gave the stock a “hold” rating in a report on Tuesday, March 10th. BTIG Research lowered shares of Hims & Hers Health from a “buy” rating to a “neutral” rating in a report on Tuesday, February 24th. Finally, Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Three research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and an average price target of $31.29.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.